

BFPT-2603 - Allergic Asthma

Overview / Indication:

BaroFold is developing a proprietary biologic for the treatment of moderate persistent to severe allergy-related asthma. Allergic Asthma results from the immune system's over-reaction to inhaled allergens such as dust mites or animal dander. The body forms IgE antibodies in response to the allergen prompting inflammation causing airway narrowing. BaroFold believes that BFPT-2603 will be able to treat allergy-related asthma with not only improved tolerability and efficacy, but also with dramatically improved safety relative to current therapies.

Attribute	TARGET PROFILE	
	Drug	
	BFPT-2603*	Xolair®
Delivery	Subcutaneous	Subcutaneous
Mechanism	Proprietary	Full-length MAb
Patients	Adults and Children	Over 12 Years Old
Safety		Black Box Warning
Efficacy	High	Moderate

* Drug candidate not approved by FDA
Xolair® is a registered trademark of Genentech

Market Opportunity - Biologics

An estimated 20 million Americans suffer from asthma. Of these, 10 million - including 3 million children - suffer specifically from allergic asthma. The total asthma and COPD market in the seven major markets was worth just over \$18.5 billion in 2006, according to MIDAS sales data and the United States accounts for 65% of these sales. The asthma/COPD market is estimated to grow to about \$19.8 billion in 2016. BaroFold believes that it can capture up to \$3 billion of this market.



Summary

- Allergic Asthma is a chronic indication for which there is a large market with unmet needs
- New therapies are needed to reduce steroid dependence and subsequent side effects
- Current second-line therapy has a Black Box warning
- BFPT-2603 is expected to have an improved safety profile relative to current therapies
- Improved tolerability and efficacy could extend label claims and reach a broader patient population

1745 38th Street • Boulder, CO 80301
p: 303-926-0337 • f: 303-926-4292 • www.barofold.com

#0002-07-K-04

BAROFOLD
IMPROVING PROTEIN THERAPEUTICS,
IMPROVING PEOPLE'S LIVES